What did @therestoreclinic actually say?
The creator called AndroGel "probably one of the worst forms of testosterone replacement therapy" and made three specific arguments: gels don't raise testosterone levels enough to relieve low-T symptoms, they still suppress natural testosterone production, and the drug's own monograph lists a half-life of 10 to 100 minutes, which the creator argues means it should be applied multiple times daily rather than once. They finished by promoting compounded transdermal testosterone from specific pharmacies using bases like HRT-base, Atrevis-base, or Versa-base.
This is a common critique in men's health and TRT circles. Some of it lands. Some of it doesn't. And one part is a meaningful misreading of pharmacokinetic data that deserves a closer look before patients start throwing away their prescriptions.
Does the science back this up?
Partially, yes. The efficacy concern is real, but the half-life argument is the weakest link in this chain.
On effectiveness: a 2012 meta-analysis by Bhasin et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that testosterone gels produce variable absorption across patients, with a meaningful subset failing to reach eugonadal levels on standard dosing. Skin thickness, application site, washing habits, and even sweating can blunt absorption significantly. So the claim that gels "won't get your testosterone levels high enough" for many patients is clinically defensible.
On suppression: this is basic HPG axis physiology. Any exogenous testosterone, regardless of delivery method, will suppress LH and FSH signaling and reduce endogenous production. The creator is correct that gels are not exempt from this. A 2004 study by Coviello et al. in JCEM showed that even low-dose transdermal testosterone suppresses gonadotropins measurably.
On the half-life argument: this is where things get muddy, and the creator oversimplifies in a way that could mislead patients.
What did they get wrong (or right)?
The half-life claim is the real problem here. The 10 to 100 minute figure in the monograph refers to the half-life of testosterone in the bloodstream after absorption, not the absorption window of the gel itself. AndroGel is designed as a depot formulation. The gel dries on the skin, and testosterone continues absorbing transdermally across the dosing interval, not in one sharp spike. The pharmacokinetic profile of AndroGel 1.62% shows relatively stable serum levels across a 24-hour period, which is the entire rationale for once-daily dosing.
Confusing the elimination half-life of free testosterone with the absorption duration of a topical depot is a basic pharmacokinetics error. It's the kind of thing that sounds compelling in a short video but doesn't hold up under scrutiny. A 2011 review by Wang et al. in the Asian Journal of Andrology laid out transdermal testosterone pharmacokinetics clearly: steady-state serum levels with once-daily application are well-documented.
What they got right: the variability in gel absorption is real, the suppression point is accurate, and the acknowledgment that some patients need a different delivery method is clinically reasonable. The promotion of specific compounding pharmacies, however, steps into territory that deserves independent verification by a patient's own prescriber.
What should you actually know?
AndroGel is not a universally poor option. It is an option with real limitations that make it a poor fit for some patients, particularly those with absorption issues or who need reliably higher serum levels. Testosterone cypionate injections remain the most studied and consistent delivery method for achieving target levels. But gels work for a subset of patients, and the FDA approved them based on clinical trial data, not marketing.
Compounded transdermal testosterone in specialty bases like Atrevis or HRT-base may offer different absorption profiles, but compounded drugs are not FDA-approved formulations. That does not make them unsafe or ineffective, but it does mean the evidentiary bar is different. Patients should have this conversation with a licensed prescriber who can monitor labs, not make the decision based on a TikTok.
One more thing: if a patient is currently using AndroGel and their symptoms persist, the answer is a conversation with their doctor and a follow-up testosterone panel, not unilaterally switching to a compounded product based on social media. Lab-guided treatment adjustments are how this is supposed to work.